ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng2 1. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred Hutch Cancer Center, Seattle, WA   LAURA: A randomized, double-blind, Phase III study of chemoradiation followed


IMBRAVE-151, A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab with or without Bevacizumab in Combination with Cisplatin plus Gemcitabine in Patients with Untreated, Advanced Biliary Tract Cancer

Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination